Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017 Journal Article

Authors: Giri, V. N.; Knudsen, K. E.; Kelly, W. K.; Abida, W.; Andriole, G. L.; Bangma, C. H.; Bekelman, J. E.; Benson, M. C.; Blanco, A.; Burnett, A.; Catalona, W. J.; Cooney, K. A.; Cooperberg, M.; Crawford, D. E.; Den, R. B.; Dicker, A. P.; Eggener, S.; Fleshner, N.; Freedman, M. L.; Hamdy, F. C.; Hoffman-Censits, J.; Hurwitz, M. D.; Hyatt, C.; Isaacs, W. B.; Kane, C. J.; Kantoff, P.; Karnes, R. J.; Karsh, L. I.; Klein, E. A.; Lin, D. W.; Loughlin, K. R.; Lu-Yao, G.; Malkowicz, S. B.; Mann, M. J.; Mark, J. R.; McCue, P. A.; Miner, M. M.; Morgan, T.; Moul, J. W.; Myers, R. E.; Nielsen, S. M.; Obeid, E.; Pavlovich, C. P.; Peiper, S. C.; Penson, D. F.; Petrylak, D.; Pettaway, C. A.; Pilarski, R.; Pinto, P. A.; Poage, W.; Raj, G. V.; Rebbeck, T. R.; Robson, M. E.; Rosenberg, M. T.; Sandler, H.; Sartor, O.; Schaeffer, E.; Schwartz, G. F.; Shahin, M. S.; Shore, N. D.; Shuch, B.; Soule, H. R.; Tomlins, S. A.; Trabulsi, E. J.; Uzzo, R.; Vander Griend, D. J.; Walsh, P. C.; Weil, C. J.; Wender, R.; Gomella, L. G.
Article Title: Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017
Abstract: Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease. © 2017 by American Society of Clinical Oncology.
Keywords: unclassified drug; gene mutation; advanced cancer; cancer risk; consensus; protein; brca1 protein; brca2 protein; prostate cancer; mismatch repair; atm protein; genetic risk; genetic screening; african american; hereditary nonpolyposis colorectal cancer; early intervention; shared decision making; cancer prognosis; hereditary breast and ovarian cancer syndrome; human; priority journal; article; protein hoxb13
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 4
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-01
Start Page: 414
End Page: 424
Language: English
DOI: 10.1200/jco.2017.74.1173
PROVIDER: scopus
PUBMED: 29236593
Notes: Article -- Export Date: 1 March 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Mark E Robson
    358 Robson
  2. Wassim Abida
    36 Abida
  3. Philip Wayne Kantoff
    60 Kantoff